Author Archives: Bruno Quinney

#CRDMO #Syngene

Syngene appoints Mittal as Managing Director and CEO 

CRDMO Syngene International has appointed Siddharth Mittal as Managing Director and Chief Executive Officer.  Mittal succeeds Peter Bains, who completed his tenure as Managing Director & CEO on 30 June 2026.   Mittal joins Syngene from Biocon Limited, where he most recently served as the Managing Director and Chief Executive Officer. Read More

#News

#Biobanking #Clinical trial

Biobanking for clinical trials: Beyond storage

This paid-for advertorial by Sampled appeared in DDW Volume 27 – Issue 3, Summer 2026. ​​​​Biological samples are critical across the clinical trial lifecycle, providing the raw material for understanding disease mechanisms, tracking biomarker dynamics, and evaluating both short and long‑term clinical outcomes.​​ Biobanking supports this lifecycle at every stage by providing secure sample collection, storage,… Read More

#Exclusive Content

The tumour microenvironment
#Aston University #Cancer research #Theranostics

UK university awarded €1.2m for cancer ‘magnetobots’ project 

Aston University has been awarded €1.2 million to fund an international project developing cancer tumour-fighting ‘magnetobots’.  The university was awarded the funding through the Marie Skłodowska-Curie Actions (MSCA) Staff Exchanges programme for the project bringing together 18 partner organisations.  The magnetobots, made from microorganisms called magnetotactic bacteria, will combine theranostic technologies to… Read More

#Cancer Research #News

Lung cancer
#Gene mutation #Genetic profiling #Japan #Lung cancer

Genetic mutations could be therapeutic target in lung cancer 

Researchers have uncovered the genetic basis of multiple primary lung cancers, shedding light on potential therapeutic targets for treatment.  A team of researchers, led by Professor Motoshi Suzuki from the Department of Molecular Oncology, Fujita Health University, Japan, along with graduate student Dat Quoc Tran from the university, distinguished… Read More

#Cancer Research #News

CAR-T therapy
#Blood cancer #CAR T-cell therapy #University College London #University of Oxford

CAR T-cell therapy selectively targets cancer mutations 

A new CAR T-cell therapy can target key mutations causing rare blood cancers and leave healthy blood cells unharmed, scientists say.  A research effort led by University College London (UCL) and the University of Oxford engineered a CAR T-cell therapy which can reprogramme a patient’s own immune cells… Read More

#Cancer Research #News

#AI #Clinical development #Clinical trial #Norstella #Real world data

How AI has revolutionised clinical development

The latest episode of the DDW ‘In Conversation With’ series is available to listen to below. This week, Bruno Quinney speaks to Suzanne Caruso, President of Strategic Intelligence and Clinical & Regulatory at Norstella. Norstella supports drug developers looking to take their treatments from pipeline to patients, finding solutions to complexities… Read More

#Featured Podcasts #Podcasts

Woman experiencing hair loss
#Alopecia #CHMP #Regulatory

CHMP adopts positive opinion for severe alopecia treatment 

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending a treatment for severe alopecia.  The recommended approval of upadacitinib is for the treatment of adult and adolescent patients with severe alopecia areata (AA), an unpredictable autoimmune disease causing a range of hair… Read More

#News #Regulatory

Patients receiving chemotherapy
#Nuclear medicine #Theranostics #University of Queensland

Patients denied personalised cancer care, study says 

Cancer patients are being denied access to a “game changer” method of treatment, a new study warns.  Health economists Dr Yufan Wang and Professor Haitham Tuffaha led a review into the value of theranostic nuclear medicine, an innovative frontier in cancer treatment, and concluded patients are being… Read More

#Cancer Research #News

Patient having a mammogram
#Breast cancer #HER2

Breast cancer patients profiled to determine drug efficacy  

Researchers have identified which breast cancer patients should be treated with anthracyclines and who can safely avoid side effects of the drugs, a study shows.  Scientists from precision oncology company Agendia published a paper in JCO Precision Oncology, which demonstrates HER2-negative (HR+HER2-) early-stage breast cancer (EBC) patients are most… Read More

#Cancer Research #News

TARGA imager
#Neurodevelopmental disorders #Organoids #Schizophrenia

Neurodevelopmental imaging in schizophrenia 

This paid-for advertorial by Lumencor appeared in DDW Volume 27 – Issue 3, Summer 2026. Studying neurodevelopmental disorders like schizophrenia is limited by model complexity and tissue access. Advanced stem cell models combined with high-speed imaging now enable scalable insight into neuronal activity and network behaviour.  Understanding neurodevelopment in schizophrenia remains a major… Read More

#Exclusive Content

Bacteria in Petri dishes
#Amazon Web Services (AWS) #Antimicrobial resistance (AMR) #Fleming Initiative

AWS supports Fleming Initiative in boost to AMR treatment 

The Fleming Initiative has enlisted the support of Amazon Web Services (AWS) to boost the organisation’s battle against antimicrobial resistance (AMR).  AWS is believed to have offered several million pounds worth of cloud and AI technology, as well as technical support, for the Initiative’s AMR intelligence platform. Read More

#News

MRI of the brain
#epilepsy #Gene therapy #Protein

New gene therapy could prevent epilepsy, study suggests 

A new type of gene therapy that only activates when the brain is under stress could stop epilepsy before it fully develops, researchers say.  In a study led by Professor Tawfeeq Shekh-Ahmed of the School of Pharmacy at the Hebrew University of Jerusalem (HU), published in Signal… Read More

#News

Diabetic eye disease
#Clinical trial #Eye health #FDA

FDA approves thyroid eye disease treatment 

The US Food and Drug Administration (FDA) has approved Lumvoa (veligrotug-vvze) as a treatment for thyroid eye disease (TED).  TED is a rare, debilitating autoimmune disease characterised by inflammation and tissue remodelling around and behind the eyes, which can lead to proptosis, diplopia, pain and vision impairment.  Lumvoa was approved… Read More

#News #Regulatory

#Assays #Drug screening #In vivo #Promega

Five questions to answer before you move your assays from 2D to 3D 

This paid-for advertorial by Promega appeared in DDW Volume 27 – Issue 3, Summer 2026.   The shift from 2D monolayers to 3D cell culture models like spheroids, organoids, and complex tissue constructs, is gaining momentum in the drug discovery space. And for good reason: 3D models better recapitulate in vivo biology, improving the predictive value of early… Read More

#Exclusive Content

Scientist in laboratory
#Clinical trial #Dicot Pharma #Investigational New Drug (IND)

FDA approves trial of erectile dysfunction treatment 

The US Food and Drug Administration (FDA) has granted Dicot Pharma approval to roll out the Phase IIb study of a treatment for erectile dysfunction.  The approval follows an Investigational New Drug (IND) Application submitted to the FDA, with the trial evaluating LIB-01 now set to commence in the US.  Dicot Pharma says LIB-01… Read More

#News #Regulatory

#Haematology #Ipsen #Mergers and acquisitions #Oncology

Ipsen acquires Kartos Therapeutics in $450m deal 

Biopharmaceutical company Ipsen has agreed a deal to acquire Kartos Therapeutics, expanding its haemato-oncology late-stage pipeline.  Ipsen will pay $450 million upfront as per the terms of the agreement, with Kartos Therapeutics shareholders eligible to receive payments of up to $1.3 million subject to regulatory approval milestones and sales-based milestones.  The merger allows Ipsen to… Read More

#Business & Investment #News